Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Shanghai Junshi Biosciences Co's enterprise value is $5,177.3 Mil.
Shanghai Junshi Biosciences Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-128.2 Mil. Therefore, Shanghai Junshi Biosciences Co's EV-to-EBITDA for today is -40.37.
The historical rank and industry rank for Shanghai Junshi Biosciences Co's EV-to-EBITDA or its related term are showing as below:
SHJBF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -142.05 Med: -21.22 Max: -3.01
Current: -40.52
During the past 10 years, the highest EV-to-EBITDA of Shanghai Junshi Biosciences Co was -3.01. The lowest was -142.05. And the median was -21.22.
SHJBF's EV-to-EBITDA is ranked worse than 100% of 399
companies
in the Biotechnology industry
Industry Median: 13.39
vs SHJBF: -40.52
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Shanghai Junshi Biosciences Co (OTCPK:SHJBF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai Junshi Biosciences Co's PE Ratio (TTM) for today is calculated as:
Shanghai Junshi Biosciences Co's share price for today is $3.35.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shanghai Junshi Biosciences Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.118.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHJBF vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Junshi Biosciences Co EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Shanghai Junshi Biosciences Co's EV-to-EBITDA falls into.
Shanghai Junshi Biosciences Co's current Enterprise Value is $5,177.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shanghai Junshi Biosciences Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-128.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Junshi Biosciences Co (SHJBF) has a EV-to-EBITDA of -40.37 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai Junshi Biosciences Co. According to the industry distribution chart, Shanghai Junshi Biosciences Co ranks #999999 out of 399 companies in the Biotechnology industry.
Is Shanghai Junshi Biosciences Co's EV-to-EBITDA too high?
Shanghai Junshi Biosciences Co's current EV-to-EBITDA is -40.37. Based on the distribution chart, Shanghai Junshi Biosciences Co ranks #999999 out of 399 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shanghai Junshi Biosciences Co has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Junshi Biosciences Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Junshi Biosciences Co ranks #999999 out of 399 companies for EV-to-EBITDA. This places Shanghai Junshi Biosciences Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.39, based on 399 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai Junshi Biosciences Co. For the Biotechnology industry, the median EV-to-EBITDA is 13.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Junshi Biosciences Co's current EV-to-EBITDA is -40.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Junshi Biosciences Co stock overvalued right now?
Shanghai Junshi Biosciences Co (SHJBF) has a current EV-to-EBITDA of -40.37. The stock's GF Value™ is $5.21, compared to a current price of $3.35 — trading 35.7% below its estimated fair value. The current EV-to-EBITDA is -40.37. Shanghai Junshi Biosciences Co's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Shanghai Junshi Biosciences Co (SHJBF), the current EV-to-EBITDA is -40.37 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Junshi Biosciences Co (SHJBF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Junshi Biosciences Co stock appears to be undervalued.
The current stock price of $3.35 is trading 35.7% below its estimated GF Value™ of $5.21.
Key valuation signals for SHJBF:
EV-to-EBITDA: -40.37
GF Value™: $5.21 vs. price of $3.35 (35.7% below fair value)
No single metric tells the full story. See the SHJBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Junshi Biosciences Co Ltd is mainly involved in the discovery, development, and commercialisation of therapeutic drugs. It focuses on the development and commercialization of several kinds of drugs, ranging from monoclonal antibodies to various drug modalities, including small molecules, ADCs, bi-specific or multi-specific antibodies, fusion proteins, nucleic acid drugs, and vaccines, as well as the exploration of next-generation therapies, including those for cancer and autoimmune diseases. The Group's portfolio includes commercialized drugs such as Tuoyi, Junmaikang, Mindewei, and Junshida, as well as products in clinical studies or in the marketing application stage. Geographically, it derives maximum revenue from Mainland China, and the rest from USA, India, and other markets.
72GF Score
Get the complete analysis for SHJBF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHJBF has been successfully added to your 
